Risk of Share-Value Dilution from the Exercise of Stock Acquisition Rights
First written in FY2018. 10 of 17 entries say "Materialised", first in FY2020-Q1. Latest entry: FY2026.
The whole theme swung hardest in 2017: 37 of 68 companies on the "Worse" side.
- FY2026WorsenedAnnual report
「As of the end of February 2026, the number of potential shares represented by stock acquisition rights was 335,560 shares, equivalent to 4.57% of the number of shares issued.」
Potential dilution increased from 98,142 shares, or 1.34%, in the fiscal year ended February 2024 to 335,560 shares, or 4.57%. - 2026-05-01MaterialisedGeneral Meetings of Shareholders
「The increase in the total number of issued shares resulted from the issuance of 18,200 shares through the exercise of stock acquisition rights.」
The Company disclosed an increase of 18,200 common shares during the fiscal year through the exercise of stock acquisition rights, demonstrating the realization of a dilution factor. - FY2025-H1MaterialisedAnnual report
「1 March 2024–31 August 2024 27,740 (Note) 1. This represents an increase resulting from the exercise of stock acquisition rights.」
During the six-month consolidated period, the exercise of stock acquisition rights increased the number of shares by 27,740, and the dilution factor from potential shares continued to materialize. - FY2025-Q1MaterialisedAnnual report
「1 March 2024–31 May 2024 (Note) 4,400 7,307,360 418 326,508 418 316,508 (Note) This represents an increase resulting from the exercise of stock acquisition rights.」
During the first quarter, the exercise of stock acquisition rights increased the number of shares by 4,400, and the dilution factor from potential shares continued to materialize. - FY2024WorsenedAnnual report
「As of 29 February 2024, the number of potential shares represented by stock acquisition rights was 98,142 shares, equivalent to 1.34% of the number of shares issued.」
Potential dilution increased from 46,380 shares, or 0.6%, to 98,142 shares, or 1.34%. - FY2024-Q2WorsenedAnnual report
「Number of stock acquisition rights (units) 614 (Note) 1 Class, details and number of shares underlying stock acquisition rights (shares) Common shares 61,400 (Note) 1 Number of stock acquisition rights (units) 365 (Note) 1 Class, details and number of shares underlying stock acquisition rights (shares) Common shares 36,500 (Note) 1」
Stock acquisition rights covering 61,400 shares were granted to 1 director and rights covering 36,500 shares were granted to 1 employee pursuant to the resolution of 10 August 2023 and issuance on 30 August. The grant of new potential shares added a dilution factor. - FY2023SoftenedAnnual report
「As of the date of submission of this document, the number of potential shares represented by stock acquisition rights was 46,380 shares, equivalent to 0.6% of the number of shares issued.」
The number of potential shares decreased from 260,200 shares, or 3.6% of shares issued, in the previous disclosure to 46,380 shares, or 0.6%, reducing the potential dilution. - FY2023-Q1WorsenedAnnual report
「Number of stock acquisition rights (units) 1,566 (Note) 1 Class, details and number of shares underlying stock acquisition rights (shares) Common shares 156,600 (Note) 1 Number of stock acquisition rights (units) 235 (Note) 1 Class, details and number of shares underlying stock acquisition rights (shares) Common shares 23,500 (Note) 1」
Stock acquisition rights covering a total of 180,100 shares were granted to directors, audit & supervisory board members and employees pursuant to the resolution of 10 March 2022. An additional potential dilution factor for existing shareholders has been introduced. - FY2022WorsenedAnnual report
「As of the date of submission of this document, the number of potential shares represented by stock acquisition rights was 260,200 shares, equivalent to 3.6% of the number of shares issued.」
During the fiscal year, the exercise of stock acquisition rights increased the number of shares by 96,078. As of the date of submission, the number of potential shares was 260,200, equivalent to 3.6% of the number of shares issued. The potential dilution increased from 2.2% in the previous disclosure. - FY2022-Q3MaterialisedAnnual report
「1 September 2021–30 November 2021 43,620 7,302,960 3,053 326,090 3,053 316,090 (Note) This represents an increase resulting from the exercise of stock acquisition rights.」
During the third quarter, the exercise of stock acquisition rights increased the number of shares by 43,620, while capital stock and capital surplus each increased by ¥3.053 million. The dilution factor continued to emerge. - FY2022-Q2MaterialisedAnnual report
「1 June 2021–31 August 2021 27,060 7,259,340 1,894 323,036 1,894 313,036 (Note) This represents an increase resulting from the exercise of stock acquisition rights.」
During the second quarter, the exercise of stock acquisition rights increased the number of shares by 27,060, and the dilution factor continued to emerge. - FY2022-Q1MaterialisedAnnual report
「1 March 2021–31 May 2021 25,398 (Note) This represents an increase resulting from the exercise of stock acquisition rights.」
During the quarter, the exercise of stock acquisition rights increased the number of shares by 25,398, and the dilution factor from potential shares continued to materialize. - FY2021MaterialisedAnnual report
「Total intrinsic value as of the end of the consolidated fiscal year ¥44.396 million Total intrinsic value, as of the exercise dates, of stock options exercised during the consolidated fiscal year ¥10.227 million」
During the fiscal year, 42,240 shares were issued upon the exercise of stock acquisition rights, and dilution from share issuance continued. The unexercised balance at year-end was 176,178 shares, while the number of potential shares as of the date of submission of this document was 158,778, equivalent to 2.2% of the number of shares issued. - FY2021-Q3MaterialisedAnnual report
「1 September 2020–30 November 2020 5,100 7,169,742 357 316,765 357 306,765 (Note) This represents an increase resulting from the exercise of stock acquisition rights.」
The exercise of stock acquisition rights increased the number of shares by 5,100 between 1 September and 30 November 2020, and the dilution factor continued to materialize. - FY2020MaterialisedAnnual report
「1 March 2019–29 February 2020 46,182 This represents an increase resulting from the exercise of stock acquisition rights. Unexercised balance 218,418」
The exercise of stock acquisition rights increased the number of shares by 46,182 during the fiscal year, leaving 218,418 unexercised at year-end, equivalent to 3.0% of the number of shares issued. The disclosure covers both the emergence and remaining balance of the dilution factor. - FY2020-Q1MaterialisedAnnual report
「1 March 2019–31 May 2019 17,460 7,135,920 1,222 314,397 1,222 304,397 (Note) 2. This represents an increase resulting from the exercise of stock acquisition rights.」
The exercise of stock acquisition rights resulted in an actual increase of 17,460 shares, making part of the potential dilution factor concrete. - FY2018First statedAnnual report
「As of the date of filing this document, the number of potential shares represented by stock acquisition rights was 104,660, equivalent to 5.2% of the number of issued shares.」
The company discloses the possibility that the exercise of stock acquisition rights granted to officers and employees could dilute existing shareholders' share value and voting rights.